Abstract
The complexity of the central nervous system (CNS) exposes it to a number of different diseases, often caused by only small variations in gene sequence or expression level. Antisense oligonucleotides and RNA interference-mediated therapies hold great promise for the treatment of CNS diseases in which neurodegeneration is linked to overproduction of endogenous protein or to synthesis of aberrant proteins coded by dominant mutant alleles. Nevertheless, difficulties related to the crossing of the blood-brain barrier, expression vectors, molecule design and to the choosing of the correct target, should be effectively solved. This review summarizes some of the most recent findings concerning the administration of potential nucleic acid-based therapeutic drugs, as well as the most promising studies performed both in vitro and in animal models of disease. Finally, some current clinical trials involving antisense oligonucleotides or silencing RNA for therapy of neurological disorders are illustrated. Results of current studies and clinical trials are exciting, and further results will be certainly reached with increasing knowledge of blood-brain barrier transporters, of genes involved in neurological disease and in new vectors for efficient delivery to brain.
Keywords: antisense oligonucleotides, rna interference, small interfering rna, brain cancer, genetic disorders, gene delivery tools, blood brain barrier, clinical trials
Current Drug Targets
Title: Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Volume: 6 Issue: 1
Author(s): A. Forte, M. Cipollaro, A. Cascino and U. Galderisi
Affiliation:
Keywords: antisense oligonucleotides, rna interference, small interfering rna, brain cancer, genetic disorders, gene delivery tools, blood brain barrier, clinical trials
Abstract: The complexity of the central nervous system (CNS) exposes it to a number of different diseases, often caused by only small variations in gene sequence or expression level. Antisense oligonucleotides and RNA interference-mediated therapies hold great promise for the treatment of CNS diseases in which neurodegeneration is linked to overproduction of endogenous protein or to synthesis of aberrant proteins coded by dominant mutant alleles. Nevertheless, difficulties related to the crossing of the blood-brain barrier, expression vectors, molecule design and to the choosing of the correct target, should be effectively solved. This review summarizes some of the most recent findings concerning the administration of potential nucleic acid-based therapeutic drugs, as well as the most promising studies performed both in vitro and in animal models of disease. Finally, some current clinical trials involving antisense oligonucleotides or silencing RNA for therapy of neurological disorders are illustrated. Results of current studies and clinical trials are exciting, and further results will be certainly reached with increasing knowledge of blood-brain barrier transporters, of genes involved in neurological disease and in new vectors for efficient delivery to brain.
Export Options
About this article
Cite this article as:
Forte A., Cipollaro M., Cascino A. and Galderisi U., Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases, Current Drug Targets 2005; 6 (1) . https://dx.doi.org/10.2174/1389450053344920
DOI https://dx.doi.org/10.2174/1389450053344920 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sepsis, Coagulation and Anticoagulants
Endocrine, Metabolic & Immune Disorders - Drug Targets The Risk of Adverse Drug Reactions in Older Patients: Beyond Drug Metabolism
Current Drug Metabolism Small Molecules in Treatment of Sepsis
Current Drug Targets NO News is not Necessarily Good News in Cancer
Current Cancer Drug Targets Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Relaxin as a Cardiovascular Drug: A Promise Kept
Current Drug Safety Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Roles of Renal Proximal Tubule Transport in the Pathogenesis of Hypertension
Current Hypertension Reviews Neuropeptide Mimetics and Antagonists in the Treatment of Inflammatory Disease: Focus on VIP and PACAP
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Stereoselective Synthesis and Applications of Compounds with N-O Bonds)
Current Organic Synthesis A Review on Emerging Drug Targets in Treatment of Schizophrenia
Current Drug Targets Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure
Current Topics in Medicinal Chemistry Levosimendan for Heart-Operated Patients: What is the State of the Art?
Recent Patents on Cardiovascular Drug Discovery The Nitric Oxide Prodrug JS-K and Its Structural Analogues as Cancer Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Development and Characterization of Cassia grandis and Bixa orellana Nanoformulations
Current Topics in Medicinal Chemistry Ethnobotanical Survey of Medicinal Plants used to Treat Cardiovascular Disorders in Ghasemloo Valley of Urmia City
Cardiovascular & Hematological Agents in Medicinal Chemistry Mas Receptor Agonists as Novel Antihypertensive Agents
Current Hypertension Reviews Management of Acute Coronary Syndromes in Patients with Renal Insufficiency
Current Cardiology Reviews Medications Affecting Functional Status in Older Persons
Current Pharmaceutical Design The Use of Propolis in Micro/Nanostructured Pharmaceutical Formulations
Recent Patents on Drug Delivery & Formulation